A 35-year-old woman with secondary infertility and normal ovulatory cycles presents for fertility counseling. Husband's semen analysis is normal. Hysterosalpingography shows patent tubes bilaterally. She has undergone 3 cycles of intrauterine insemination (IUI) with clomiphene citrate (CC) 100 mg/day (days 5–9) without conception. Serum progesterone on day 21 is 8 ng/mL (ovulation confirmed). What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **unexplained infertility** with normal ovulation (confirmed by day-21 progesterone >8 ng/mL), normal semen analysis, and patent tubes. She has failed 3 cycles of CC-IUI despite documented ovulation. ## Why Gonadotropin-Stimulated IUI is Next **Key Point:** When CC-IUI fails after 3–4 cycles in a patient with confirmed ovulation, the next evidence-based step is **escalation to gonadotropin-stimulated IUI**, not dose escalation of CC or immediate IVF. ### Rationale: 1. **CC has ceiling efficacy**: CC works by blocking estrogen feedback and increasing FSH. In patients who ovulate on CC but remain infertile, further CC dose escalation rarely improves pregnancy rates; it may worsen cervical mucus and endometrial receptivity. 2. **Gonadotropins offer physiologic advantage**: Exogenous FSH (75–150 IU/day) allows direct dose titration to achieve **multifollicular development** (typically 2–3 mature follicles), increasing oocyte yield per cycle without the adverse effects of CC on endometrium or cervical mucus. 3. **IUI amplification**: Multiple oocytes + IUI = higher fecundity rate than single ovulation + IUI. 4. **Cost-effective escalation**: Gonadotropin-IUI is less invasive and expensive than IVF, making it the appropriate intermediate step before ART. 5. **ASRM/NICE guidance**: For unexplained infertility after failed CC-IUI, gonadotropin-IUI is recommended before IVF. ## Clinical Pearl **Ovulation ≠ Fertility**: Documented ovulation does not exclude other causes of infertility (e.g., subtle oocyte defects, suboptimal endometrial receptivity, or male factor not captured by basic semen analysis). Escalating stimulus intensity (gonadotropins) addresses these by increasing oocyte number and quality. ## Why Each Distractor is Wrong **Option 0 (Increase CC to 150 mg/day):** - CC dose escalation beyond 100 mg/day has **no proven benefit** in patients who already ovulate on standard doses. - Further CC increases risk of **ovarian hyperstimulation** (though rare with CC alone) and worsens **antiestrogenic effects** on cervical mucus and endometrium. - This represents futile repetition, not evidence-based escalation. **Option 2 (Proceed directly to IVF):** - **Premature escalation**: IVF is reserved for failed gonadotropin-IUI, tubal disease, severe male factor, or endometriosis—not as second-line after CC-IUI failure in unexplained infertility. - **Cost and morbidity**: IVF carries higher cost, OHSS risk, and procedural burden; it should not be offered when a less invasive, effective intermediate step exists. - Violates the principle of **stepwise escalation** in fertility management. **Option 3 (Add metformin to CC):** - **No indication**: Metformin is indicated for **PCOS with insulin resistance** or anovulation, not for ovulatory women with unexplained infertility. - This patient has **normal ovulation** (day-21 progesterone 8 ng/mL), so insulin-sensitizing therapy is not evidence-based. - Adds cost and side effects without mechanistic justification.